Myriad Genetics (NASDAQ:MYGN) Given New $11.50 Price Target at Piper Sandler
Myriad Genetics (NASDAQ:MYGN – Free Report) had its price objective cut by Piper Sandler from $14.00 to $11.50 in a research note issued to investors on Tuesday morning,Benzinga reports. They currently have a neutral rating on the stock. Several other equities research analysts have also commented on MYGN. Leerink Partners lowered Myriad Genetics from an […]
Myriad Genetics (NASDAQ:MYGN – Free Report) had its price objective cut by Piper Sandler from $14.00 to $11.50 in a research note issued to investors on Tuesday morning,Benzinga reports. They currently have a neutral rating on the stock. Several other equities research analysts have also commented on MYGN. Leerink Partners lowered Myriad Genetics from an […]
